<DOC>
	<DOCNO>NCT00113282</DOCNO>
	<brief_summary>Interleukin-2 ( IL-2 ) increase number CD4 cell HIV-1 infect patient CD4 cell count 200/mm3 , activity patient treatment failure low CD4 cell count unknown . This study test efficacy safety IL-2 optimized antiretroviral regimen patient CD4 count 200/mm3 plasma viral load 10,000 HIV RNA copies/ml .</brief_summary>
	<brief_title>Efficacy Adding Interleukin-2 Optimized Antiretroviral Regimen HIV Patients Therapeutic Failure ( ANRS123 )</brief_title>
	<detailed_description>IL-2 produce naturally body help CD4 cell multiply . In early study HIV-infection , patient control viral load high level CD4 count ( 200/mm3 ) receive IL-2 , experience increase CD4 cell count superior observed antiretroviral therapy alone . The efficacy IL-2 viral load high CD4 cell count low know . The purpose multicentric national study compare effect optimize antiretroviral regimen without IL-2.The choice antiretroviral regimen make genotype resistance test . Ninety eight HIV-1-infected patient experience advanced treatment failure CD4 count 200/mm3 plasma viral load 10,000 HIV RNA copies/ml , randomly assign one two treatment group : without IL-2 . The group IL-2 receive dose 4.5 million International unit subcutaneous injection twice day 5 day ( total 8 cycle , end Week 42 ) , first two cycle 4 week apart , follow cycle 6 week apart . Evaluation do week 52 W76 . The primary endpoint proportion patient reach absolute CD4 count 200/mm3 Week 52 . Secondary endpoint include proportion patient increase CD4 count 50/mm3 Week 00 Week 24 , Week 00 Week 52 , occurrence HIV-related event , drug safety evolution CD4 cell HIV RNA HIV DNA load time .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Adult patient proven HIV1infection Prior current exposition least 1 molecule 3 antiretroviral class ( NRTI , NNRTI PI ) In situation therapeutic failure ongoing regimen Patients include MacrolinÂ® expand French access program</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Treatment failure</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>